A prodrug form of MLN2238
Related Products
Active Metabolite(s)
18385MLN2238
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

MLN9708

Item No. 18386

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid
CAS Number
1201902-80-8
Synonyms
  • Ixazomib Citrate
Molecular Formula
C20H23BCl2N2O9
Formula Weight
517.1
Purity
≥95%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMF:PBS (pH 7.2) (1:1): 0.5 mg/mlDMSO: 2 mg/ml
λmax
282 nm
SMILES
ClC1=C(C(NCC(N[C@@H](CC(C)C)B2OC(CC(O)=O)(C(O)=O)CC(O2)=O)=O)=O)C=C(Cl)C=C1
InChi Code
InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1
InChi Key
YTXSYWAKVMZICI-PVCZSOGJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $66

    Add

    10 mg

    $98

    Add

    25 mg

    $163

    Add

    50 mg

    $229

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    MLN9708 is a prodrug form of the proteasome inhibitor MLN2238 (Item No. 18385).1,2 It is converted to MLN2238 via hydrolysis in the plasma.1 MLN9708 inhibits the 20S proteasome (IC50 = 8.4 nM for the human enzyme) and binds to caseinolytic protease P (Kd = 7,300 nM for the S. aureus enzyme).3,4 It inhibits the proliferation of RPMI-8226, U266B, and ARH-77 multiple myeloma cells with IC50 values of 49.4, 67, and 43.5 nM, respectively.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kupperman, E., Lee, E.C., Cao, Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70(5), 1970-1980 (2010).

    2. Garcia-Gomez, A., Quwaider, D., Canavese, M., et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin. Cancer Res. 20(6), 1542-1554 (2014).

    3. Lei, M., Feng, H., Bai, E., et al. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer. Org. Biomol. Chem. 17(3), 683-691 (2019).

    4. Ju, Y., He, L., Zhou, Y., et al. Discovery of novel peptidomimetic boronate ClpP inhibitors with noncanonical enzyme mechanism as potent virulence blockers in vitro and in vivo. J. Med. Chem. 63(6), 3104-3119 (2020).